Beam Therapeutics
BEAM | NASDAQ
$20.94
-$1.89 (-8.28%)
At close: Nov 16, 2026, 4:00 PM ET
$21.10
+$0.16 (+0.76%)
After-hours:
Nov 16, 2026, 7:55 PM ET
Beam Therapeutics Company Profile
Company profile explainedCompany Profile
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Key Executives
| Name | Position |
|---|---|
| John Evans | Chief Executive Officer & Director |
| Christine Bellon | Chief Legal Officer & Corporate Secretary |
| Manmohan Singh | Chief Technology Officer |
| Sravan Kumar Emany | Chief Financial Officer |
| Amy Simon | Chief Medical Officer |
| Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer |
| David R. Liu | Co-Founder |
| Feng Zhang | Co-Founder |
| Giuseppe Ciaramella | President |
| J. Keith Joung | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 16, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Sep 25, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 29, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
Beam Therapeutics
| Country | United States |
| IPO Date | Feb 6, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 540 |
| CEO | John Evans |
Contact Details
238 Main Street Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | BEAM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001745999 |
| CUSIP Number | 07373V105 |
| ISIN Number | US07373V1052 |
| SIC Code | 2836 |
Recent News
- 4 days ago / seekingalpha.comBeam Therapeutics: Market Selling Promising Data Readouts Doesn't Add Up
- 5 days ago / zacks.comBEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
- 6 days ago / globenewswire.comBeam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
- 14 days ago / zacks.comBeam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
- 18 days ago / zacks.com3 Promising Genomics Stocks to Add to Your Portfolio Now
- 19 days ago / zacks.comBeam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?
- 21 days ago / seekingalpha.comBeam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
- 21 days ago / marketbeat.comBeam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
- 21 days ago / globenewswire.comBeam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
- 1 month ago / fool.comCathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Add to Watchlist
Select watchlists to add or remove BEAM